{"groups":[{"description":"Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \\> 100-500/uL following the nadir or the next chemotherapy course begins.\n\nCaspofungin Acetate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG000","title":"Arm I (Caspofungin Acetate)"},{"description":"Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.\n\nFluconazole: Given IV or PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"FG001","title":"Arm II (Fluconazole)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"29"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"36"}],"type":"Institutional diagnosis of IFD"},{"reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"44"}],"type":"Begin conditioning for HSCT"},{"reasons":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"23"}],"type":"Refractory or relapsed AML"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"257"},{"groupId":"FG001","numSubjects":"260"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"117"},{"groupId":"FG001","numSubjects":"115"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"145"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}